Potential therapies can be developed for the following by using T-box genes to control N-myc: Cancer treatments. Stem cell therapies to treat chronic and acute diseases. Genetic disorders involving T-box genes.
[更多]
Much faster optimization (only 5-10 minutes on CPU and 25-30 seconds on GPU) compared to the hours required for existing algorithms. Reduces radiation dosage to the organs at risk (OARs) by computing a more conformed treatment volume for the target (compared to IMRT treatment plans).
[更多]
Cutaneous T-cell Lymphomas and other cancers
[更多]
The invention has a wide range of biomedical and device applications including phase-change triggered drug delivery, morphology-controlled pharmacokinetics, phase-change activated MRI contrast agents, and biotemplating of materials for nanoelectronics.
[更多]
Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders
[更多]
| |< <- | [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] | -> >| |
